★
Market Access & Post Approval
One team turns EMA approval into commercial launch, without interruptions.
The CRO trusted by teams that can't afford to lose momentum after approval
Market access and post approval, from EMA decision to commercial launch
Approval doesn't guarantee market access. One team carries your product through pricing and reimbursement, payer negotiations and post-approval variations — so momentum never stalls between the EMA decision and your first sale.
HTA dossiers
Pricing & reimbursement
Payer negotiations
Post-approval lifecycle
Request a meeting
Tell us where your launch stands. We respond within 24-48 business hours.
Response within 24-48h
No obligation
Market access pathway in progress
Interactive simulator
👆 Click each milestone to see how we manage your launch at that stage
HTA dossier submitted
Pricing position defined
Payer briefing prepared
4Market access milestones
4Payer interactions managed
1Team, entire pathway
Illustrative example of a market access pathway
A CRO you can trust
Direct, transparent communication in every pricing and reimbursement negotiation, no middlemen.
Budget adapted to your company
Accompaniment plans adjusted to your company's size and launch markets.
No team handoffs
The same point of contact from EMA approval through to commercial launch.
Continuous follow-up
We don't disappear after approval — we stay with you until the product is on the market.
How we work
From EMA approval to commercial launch
01
Market access assessment
We review your approval dossier and the HTA landscape in your target markets.
02
Pricing & reimbursement strategy
We design the value story and the submission sequence, market by market.
03
Support through the negotiation
We accompany every interaction with HTA bodies and payers, with no change of contact.
04
Post-launch follow-up
We monitor variations, price renewals and early commercial performance.
What's included
One single team for every step from approval to launch
02
Value & HTA dossiers
We prepare health technology assessment dossiers tailored to each national agency.
03
Pricing & reimbursement strategy
We define price positioning and the submission sequence across your priority markets.
04
Payer negotiations
We accompany meetings with HTA bodies and reimbursement committees.
05
Post-approval variation management
Updates, renewals and price variations handled without losing continuity.
06
Multi-country coordination
We align the launch sequence when market access spans several member states.
We adapt to you
A plan tailored to your launch, not a fixed rate for everyone
Market access assessment
A first session to review your approval dossier and the HTA landscape in your target markets before committing budget.
Tailored launch strategy
We design the pricing, reimbursement and launch sequencing plan adjusted to your budget.
Post-launch support
We keep managing variations, renewals and commercial performance once the product is launched.
Why choose Geistek
Approval isn't the finish line — it's the start of market access
Friction point
Approval doesn't guarantee market access
Many teams start HTA work only after approval, adding months to the real time to market.
Geistek solution
We prepare the value dossier before approval
We start HTA work in parallel with the final regulatory phase, not after.
Friction point
Every country requires a different dossier
Rebuilding the value story from scratch for each market wastes time and budget.
Geistek solution
We coordinate the country-by-country sequence
We prioritise markets and adapt the value story without duplicating effort.
Friction point
Follow-up stops after launch
Many CROs disappear exactly when price variations and renewals start.
Geistek solution
Ongoing support through the commercial lifecycle
We keep managing price variations and renewals after launch.
Our model
A partner integrated from approval to launch
One team, not a one-off delivery
We accompany every negotiation and every submission together with your team, not just the initial filing.
01
Real experience with HTA bodies
Direct knowledge of how to negotiate price and reimbursement with Europe's main payers.
02
Coverage across Spain and the EU
Market access management with local presence and the ability to coordinate at a European level.
03
Connected to your regulatory strategy
Market access is coordinated with the rest of your programme, not in isolation.
Coverage across Spain + the European Union
Coordination of the launch sequence across different member states when market access requires it.
Frequently asked questions
Common questions about this accompaniment
How long does market access take after EMA approval?
It varies by country and therapeutic area, but pricing and reimbursement processes typically run in parallel across markets rather than one after another. Starting the value dossier work before approval is what keeps the overall timeline as short as possible.
Do you work with value dossiers already prepared, or from scratch?
Both. We can build the HTA and value dossier from the clinical evidence available, or pick up an existing dossier and adapt it for the specific requirements of each national agency.
Do you cover pricing negotiations in several countries at once?
Yes. We prioritise your target markets and coordinate the submission and negotiation sequence so the same value story is adapted, not duplicated, country by country.
What happens if there's a post-approval variation?
We keep managing price variations, renewals and post-approval updates as part of the same engagement, so market access support doesn't stop once the product launches.
Let's start the conversation
Tell us where your launch stands
We'll review your approval context and tell you, with no obligation, how this accompaniment would fit.
Request a meeting
We respond within 24-48 business hours.
Response within 24-48h
Plan adjusted to your launch
No obligation
